Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) - Total Liabilities

Latest as of September 2025: CN¥877.24 Million CNY ≈ $128.37 Million USD

Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has total liabilities worth CN¥877.24 Million CNY (≈ $128.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688117 cash generation efficiency to assess how effectively this company generates cash.

Cheng Du Sheng Nuo Biotec Co. Ltd. A - Total Liabilities Trend (2017–2024)

This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Cheng Du Sheng Nuo Biotec Co. Ltd. A to evaluate the company's liquid asset resilience ratio.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
Sitronix Technology Corp
TW:8016
Taiwan NT$5.49 Billion
Navigator Global Investments Ltd
AU:NGI
Australia AU$164.23 Million
Rezolve AI Limited Ordinary Shares
NASDAQ:RZLV
USA $94.39 Million
Shenzhen Strongteam Decoration Engineering Co Ltd
SHE:002989
China CN¥786.37 Million
Shandong Longhua New Material Co. Ltd.
SHE:301149
China CN¥1.22 Billion
Shenyu Communication Technology Inc
SHE:300563
China CN¥355.83 Million
Imperial Metals Corporation
TO:III
Canada CA$766.00 Million
Gryphon Capital Income Trust
AU:GCI
Australia AU$7.51 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.46 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.85 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cheng Du Sheng Nuo Biotec Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)

The table below shows the annual total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥729.58 Million
≈ $106.76 Million
+67.48%
2023-12-31 CN¥435.63 Million
≈ $63.75 Million
+54.88%
2022-12-31 CN¥281.27 Million
≈ $41.16 Million
+64.03%
2021-12-31 CN¥171.48 Million
≈ $25.09 Million
+10.34%
2020-12-31 CN¥155.41 Million
≈ $22.74 Million
+9.09%
2019-12-31 CN¥142.46 Million
≈ $20.85 Million
-5.59%
2018-12-31 CN¥150.90 Million
≈ $22.08 Million
+41.74%
2017-12-31 CN¥106.46 Million
≈ $15.58 Million
--

About Cheng Du Sheng Nuo Biotec Co. Ltd. A

SHG:688117 China Drug Manufacturers - Specialty & Generic
Market Cap
$861.57 Million
CN¥5.89 Billion CNY
Market Cap Rank
#9802 Global
#2766 in China
Share Price
CN¥37.41
Change (1 day)
+0.46%
52-Week Range
CN¥30.60 - CN¥48.78
All Time High
CN¥48.78
About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more